Trial Profile
A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs GZ 402668 (Primary) ; GZ 402668 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Genzyme Corporation
- 28 Oct 2017 Results of pharmacodynamic effects of intravenous and subcutaneous doses of GLD52 on innate and adaptive immune cells presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
- 28 Oct 2017 Results (n=44) assessing safety, tolerability and pharmacodynamics of ascending single intravenous (IV) and subcutaneous (SC) doses of GLD52 in patients with progressive MS, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
- 28 Apr 2017 Results (n=44) presented at the 69th Annual Meeting of the American Academy of Neurology.